Quotes 5-day view Delayed Swiss Exchange
10/26/2020
10/27/2020
10/28/2020
10/29/2020
10/30/2020
Date
574.4(c)
577.8(c)
556(c)
553.2(c)
555.2(c)
Last
178 762
201 449
250 476
189 787
270 151
Volume
-0.10% +0.59% -3.77% -0.50% +0.36% Change
Sales 2020
6 166 M 6 725 M 6 725 M
Net income 2020
858 M 936 M 936 M
Net Debt 2020
2 825 M 3 081 M 3 081 M
P/E ratio 2020
47,1x
Yield 2020
0,53%
Sales 2021
6 633 M 7 235 M 7 235 M
Net income 2021
986 M 1 075 M 1 075 M
Net Debt 2021
2 428 M 2 648 M 2 648 M
P/E ratio 2021
40,2x
Yield 2021
0,58%
Capitalization
41 097 M 44 852 M 44 824 M
EV / Sales 2020
7,12x
EV / Sales 2021
6,56x
Nbr of Employees
15 913
Free-Float
99,6%
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for...
Notations Surperformance© of Lonza Group AG
Trading Rating : Investor Rating :
All news about LONZA GROUP AG
News in other languages on LONZA GROUP AG
LONZA GROUP AG - 10/02
The stock is approaching a major resistance level
BUY
Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends LONZA GROUP AG
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
570,71 CHF
Last Close Price
553,20 CHF
Spread / Highest target
27,6%
Spread / Average Target
3,16%
Spread / Lowest Target
-41,1%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
